Representative images of two patients successfully treated with osimertinib following acquired resistance to icotinib.

Representative images of two patients successfully treated with osimertinib following acquired resistance to icotinib.

<p><b>(A)</b> Case 1: Retroperitoneal metastasis with malignant ascites. Contrast-enhanced abdominal CT scans before osimertinib initiation (left) and after 22 months of osimertinib treatment (right). <b>(B)</b> Case 2: Multiple bone metastases. PET-CT scan before osime...

Full description

Saved in:
Bibliographic Details
Main Author: Mengzhi Cheng (22648018) (author)
Other Authors: Jianbin Zhang (230061) (author), Lili Jin (2869598) (author), Caihua Yu (715599) (author), Zhonghai Xie (22648021) (author), Dong Li (212687) (author), Qinhua Gu (361108) (author), Qibin Shen (9470343) (author)
Published: 2025
Subjects:
Medicine
Cell Biology
Cancer
Biological Sciences not elsewhere classified
osimertinib upon identification
corin trial indicated
central nervous system
2 adverse events
retrospective study evaluated
higher aes occurred
although overall survival
potential dfs benefit
enrolled 37 patients
completely resected egfr
year dfs rate
year disease
study suggests
free survival
aes ),
tolerated profile
successfully switched
risk factors
nsclc ).
evidence regarding
adjuvant icotinib
4 %.
31 months
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items